UNSPSC 51381509: Triflumidate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H14F3NO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V6G94Z48FK, chemically known as carbanilic acid, m-benzoyl-n-((trifluoromethyl)sulfonyl)-, ethyl ester but generally known as triflumidate, which bears US NIH Compound Identifier 32259. European Medicines Agency schedules Triflumidate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11286MIG.

UNSPSC 51381509 Triflumidate is a Commodity code, but the recent state and local opportunities tagged under it do not procure triflumidate itself — instead they solicit naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. The code shows a mismatch between its nominal scope and actual purchasing activity. State and local governments using this code are buying pharmaceutical products and drug-management systems, primarily through county health departments, state health and human services agencies, and cooperative purchasing alliances. Issuing bodies include Seminole County, Florida (health procurement), the Texas Health and Human Services Commission (pharmacy benefit program design), and the Minnesota Multistate Cooperative Purchasing Alliance (multi-state pharmaceutical distribution). Work solicited ranges from direct product supply through competitive bidding to market-research RFIs exploring direct-to-manufacturer pharmacy programs and cooperative purchasing arrangements for generic pharmaceuticals across multiple jurisdictions.

Geographic activity centers on Florida, Texas, and Minnesota, with the Minnesota cooperative purchasing vehicle spanning multiple participating states including Oregon. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, and the Minnesota Department of Administration's MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products through authorized wholesalers with an effective date of July 1, 2026. The Texas HHS Commission issued an RFI (posted April 3, 2026) to explore vendor capabilities for a direct-to-manufacturer prescription program, signaling state-level interest in restructuring pharmacy procurement models. The code shows modest recent activity with no explicit set-aside designations noted across the opportunities reviewed.